Development of a novel fluorescent imaging probe for tumor hypoxia by use of a fusion protein with oxygen-dependent degradation domain of HIF-1&agr;
暂无分享,去创建一个
[1] Masahiro Hiraoka,et al. Optical Imaging of Tumor Hypoxia and Evaluation of Efficacy of a Hypoxia-Targeting Drug in Living Animals , 2005, Molecular imaging.
[2] Yuichi Makino,et al. Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway* , 1999, The Journal of Biological Chemistry.
[3] L. Huang,et al. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .
[4] P. Okunieff,et al. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.
[5] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[6] M. Ivan,et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.
[7] G. Semenza,et al. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. , 1999, Annual review of cell and developmental biology.
[8] S. McKnight,et al. A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.
[9] Masahiro Hiraoka,et al. Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. , 2004, International journal of oncology.
[10] J. Brown,et al. Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.
[11] Masahiro Hiraoka,et al. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. , 2002, Cancer research.
[12] M. Hiraoka,et al. Mechanism of hypoxia‐specific cytotoxicity of procaspase‐3 fused with a VHL‐mediated protein destruction motif of HIF‐1α containing Pro564 , 2006, FEBS letters.
[13] M. Hiraoka,et al. Antitumor protein therapy; Application of the protein transduction domain to the development of a protein drug for cancer treatment , 2006, Breast cancer.
[14] Eamonn R. Maher,et al. Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.
[15] G. Semenza,et al. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.
[16] M. Hiraoka,et al. Tumor hypoxia: A target for selective cancer therapy , 2003, Cancer science.
[17] Michael I. Wilson,et al. C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.
[18] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.